Cellebrite DI Ltd. (CLBT): one to watch?

Watch, not buy yet — a real growth-slowdown plus surprise CEO change caused this crash, and it's unclear if the new boss can fix deal-timing problems.

👀 WATCH Fundamentals59/100

Fell 33% in 3 trading day(s) — now $10.80

Why CLBT dropped

Cellebrite (digital forensics software) missed Q2 revenue slightly, cut full-year revenue and bookings (ARR) guidance, and abruptly swapped CEOs on the same day — a rare combination that spooked investors even though profit per share actually beat expectations.

Fwd P/E 16.8Op margin 5.3%Rev growth 15.8%Debt/equity 4.3%Analyst upside 56.1%

How this scored 59/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 11.4%

✅ Generates cash Free cash flow $113M

✅ Not drowning in debt Debt/equity 4.3% (limit 200%)

✅ Can pay its bills Current ratio 1.6 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 9/25

Operating margin 5.3% 2/9

Net profit margin 11.4% 5/8

Return on equity 12.4% 3/8

Growth Is it getting bigger, or dying? 14/25

Revenue growth 15.8% 6/9

Earnings growth -75.1% 0/8

Expected profit change 222.2% 8/8

Value Is it cheap right now? 16/25

Forward P/E 16.8 7/10

PEG ratio unknown 2/8

Analyst target upside 56.1% 7/7

Balance sheet Will it survive? 20/25

Debt / equity 4.3% 10/10

Current ratio 1.6 3/8

Free cash flow $113M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for CLBT — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-14. Research only — not financial advice.